137 related articles for article (PubMed ID: 36277287)
1. Combining targeted and systematic prostate biopsy improves prostate cancer detection and correlation with the whole mount histopathology in biopsy naïve and previous negative biopsy patients.
Mischinger J; Schöllnast H; Zurl H; Geyer M; Fischereder K; Adelsmayr G; Igrec J; Fritz G; Merdzo-Hörmann M; Elstner J; Schmid J; Triebl A; Trimmel V; Reiter C; Steiner J; Rosenlechner D; Seles M; Pichler GP; Pichler M; Riedl J; Schöpfer-Schwab S; Strobl J; Hutterer GC; Zigeuner R; Pummer K; Augustin H; Ahyai S; Mannweiler S; Fuchsjäger M; Talakic E
Front Surg; 2022; 9():1013389. PubMed ID: 36277287
[TBL] [Abstract][Full Text] [Related]
2. Targeted multiparametric magnetic resonance imaging/transrectal ultrasound-guided (mpMRI/TRUS) fusion prostate biopsy versus systematic random prostate biopsy: A comparative real-life study.
Pham THN; Schulze-Hagen MF; Rahnama'i MS
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1962. PubMed ID: 38217298
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of the relationship between PI-RADS scores and the pathological results of targeted biopsy based on MRI].
Wang YM; Shang JW; Dong L; Liang LH; Zhao RZ; Liang C; Wang SQ; Xia W; Cheng G; Hua LX
Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):942-947. PubMed ID: 37968079
[No Abstract] [Full Text] [Related]
4. Comparison of Targeted Biopsy and Combined Biopsy to Avoid Unnecessary Systematic Biopsy in Patients with PI-RADS 5 Lesions.
Yuan C; Li D; Wu J; Shen Q; Wang X; Xiao J; He Z; Zhou L; Li X; Liu Y; Zhao Z
Biomedicines; 2023 Nov; 11(12):. PubMed ID: 38137384
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Regional Saturation Biopsy, Targeted Biopsy, and Systematic Biopsy in Patients with Prostate-specific Antigen Levels of 4-20 ng/ml: A Prospective, Single-center, Randomized Controlled Trial.
Jiang X; Chen M; Tian J; Li X; Liu R; Wang Y; Zhao Y; Peng S; Niu Y; Xu Y
Eur Urol Oncol; 2023 Dec; ():. PubMed ID: 38158249
[TBL] [Abstract][Full Text] [Related]
6. Added Value of Prostate-specific Antigen Density in Selecting Prostate Biopsy Candidates Among Men with Elevated Prostate-specific Antigen and PI-RADS ≥3 Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate: A Systematic Assessment by PI-RADS Score.
Pellegrino F; Stabile A; Sorce G; Quarta L; Robesti D; Cannoletta D; Cirulli G; Barletta F; Scuderi S; Mazzone E; de Angelis M; Brembilla G; De Cobelli F; Salonia A; Montorsi F; Briganti A; Gandaglia G
Eur Urol Focus; 2023 Oct; ():. PubMed ID: 37865591
[TBL] [Abstract][Full Text] [Related]
7. Value of perilesional biopsies in multiparametric magnetic resonance imaging-targeted biopsy and systematic biopsy in detection of prostate cancer: results of a prospective, non-randomized, surgeon-blinded study.
Duwe G; Schmitteckert M; Haack M; Sparwasser P; Dotzauer R; Thomas A; Tsaur I; Brandt MP; Kurosch M; Mager R; Haferkamp A; Boehm K; Höfner T
World J Urol; 2024 May; 42(1):297. PubMed ID: 38709326
[TBL] [Abstract][Full Text] [Related]
8. Creating a novel multiparametric magnetic resonance imaging-based biopsy strategy for reducing unnecessary prostate biopsies: a retrospective cohort study.
Wang C; Shen D; Yuan L; Dong Q; Xu S; Liu Y; Xiao J
Quant Imaging Med Surg; 2024 Feb; 14(2):2021-2033. PubMed ID: 38415121
[TBL] [Abstract][Full Text] [Related]
9. PI-RADS upgrading as the strongest predictor for the presence of clinically significant prostate cancer in patients with initial PI-RADS-3 lesions.
Kwe J; Baunacke M; Boehm K; Platzek I; Thomas C; Borkowetz A
World J Urol; 2024 Feb; 42(1):84. PubMed ID: 38363332
[TBL] [Abstract][Full Text] [Related]
10. [Clinical study of artificial intelligence-guided image fusion assisted transperineal prostate biopsy].
Hu J; Zhao XD; Zhou YL; Dong N; Ma MF; Chen YH; Sheng ZC; Dong J; He CQ; Xu S
Zhonghua Nan Ke Xue; 2023 Aug; 29(8):729-735. PubMed ID: 38619521
[TBL] [Abstract][Full Text] [Related]
11. Combined MRI-TRUS fusion targeted and systematic biopsy versus systematic biopsy alone for the detection of prostate cancer: protocol for a prospective single-centre trial.
Liu W; Kadier A; Shen D; He Y; Dong S; Zhu K; Xu G; Zhao B; Mao S; Guo C; Yao X; Wei Q; Han D; Yang B
BMJ Open; 2024 Mar; 14(3):e080593. PubMed ID: 38431292
[TBL] [Abstract][Full Text] [Related]
12. Performance of standard systematic biopsy versus MRI/TRUS fusion biopsy using the Navigo® system in contemporary cohort.
Nativ O; Shefler A; Bejar J; Peschansky S; Lavi A; Michael C; Nativ O
Urol Oncol; 2024 May; 42(5):159.e1-159.e7. PubMed ID: 38431487
[TBL] [Abstract][Full Text] [Related]
13. Optimizing multiparametric magnetic resonance imaging-targeted biopsy and detection of clinically significant prostate cancer: the role of perilesional sampling.
Noujeim JP; Belahsen Y; Lefebvre Y; Lemort M; Deforche M; Sirtaine N; Martin R; Roumeguère T; Peltier A; Diamand R
Prostate Cancer Prostatic Dis; 2023 Sep; 26(3):575-580. PubMed ID: 36509930
[TBL] [Abstract][Full Text] [Related]
14. Beyond Prostate Imaging Reporting and Data System: Combining Magnetic Resonance Imaging Prostate Imaging Reporting and Data System and Prostate-Specific Membrane Antigen-Positron Emission Tomography/Computed Tomography PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate Cancer.
Emmett L; Papa N; Hope TA; Fendler W; Calais J; Burger I; Eiber M; Barbato F; Moon D; Counter W; John N; Xue A; Franklin A; Thompson J; Rasiah K; Frydenberg M; Yaxley J; Buteau J; Agrawal S; Ho B; Nguyen A; Liu V; Lee J; Woo H; Hsiao E; Sutherland T; Perry E; Stricker P; Hofman MS; Kasivisvanathan V; Roberts M; Murphy D
J Urol; 2024 May; ():101097JU0000000000004010. PubMed ID: 38758680
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic performance of regional systematic biopsy for prostate cancer stratified by PI-RADS and histologic zones.
Sun Z; Liu Y; Yu W; Wang H; Shen Q; Zhang C
Insights Imaging; 2024 May; 15(1):118. PubMed ID: 38755502
[TBL] [Abstract][Full Text] [Related]
16. Follow-up of men with a PI-RADS 4/5 lesion after negative MRI/Ultrasound fusion biopsy.
Kornienko K; Reuter M; Maxeiner A; Günzel K; Kittner B; Reimann M; Hofbauer SL; Wiemer LE; Heckmann R; Asbach P; Wendler JJ; Schostak M; Schlomm T; Friedersdorff F; Cash H
Sci Rep; 2022 Aug; 12(1):13603. PubMed ID: 35948575
[TBL] [Abstract][Full Text] [Related]
17. Risk-Adapted Strategy Combining Magnetic Resonance Imaging and Prostate-Specific Antigen Density to Individualize Biopsy Decision in Patients With PI-RADS 3 ``Gray Zone'' Lesions.
Akpinar C; Oz DK; Oktar A; Suer E; Ozden E; Haliloglu N; Gulpinar O; Gokce MI; Gogus C; Baltaci S
Clin Genitourin Cancer; 2024 Jun; 22(3):102071. PubMed ID: 38555682
[TBL] [Abstract][Full Text] [Related]
18. The Added Value of Side-specific Systematic Biopsy in Patients Diagnosed by Magnetic Resonance Imaging-targeted Prostate Biopsy.
Bourgeno HA; Jabbour T; Baudewyns A; Lefebvre Y; Ferriero M; Simone G; Fourcade A; Fournier G; Oderda M; Gontero P; Bernal-Gomez A; Mastrorosa A; Roche JB; Abou Zahr R; Ploussard G; Fiard G; Halinski A; Rysankova K; Dariane C; Delavar G; Anract J; Barry Delongchamps N; Bui AP; Taha F; Windisch O; Benamran D; Assenmacher G; Vlahopoulos L; Guenzel K; Roumeguère T; Peltier A; Diamand R
Eur Urol Oncol; 2024 Jan; ():. PubMed ID: 38272745
[TBL] [Abstract][Full Text] [Related]
19. Value of cognitive fusion targeted and standard systematic transrectal prostate biopsy for prostate cancer diagnosis.
Yu LP; Du YQ; Sun YR; Qin CP; Yang WB; Huang ZX; Xu T
Asian J Androl; 2024 May; ():. PubMed ID: 38783630
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic Utility of Artificial Intelligence-assisted Transperineal Biopsy Planning in Prostate Cancer Suspected Men: A Prospective Cohort Study.
Guenzel K; Lukas Baumgaertner G; Padhani AR; Luckau J; Carsten Lock U; Ozimek T; Heinrich S; Schlegel J; Busch J; Magheli A; Struck J; Borgmann H; Penzkofer T; Hamm B; Hinz S; Alexander Hamm C
Eur Urol Focus; 2024 Apr; ():. PubMed ID: 38688825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
